Vistagen Therapeutics Reports $1.5M Revenue and $13M Net Loss for Quarter Ended June 30, 2026

Vistagen Therapeutics, Inc. reported its financial results for the three months ended June 30, 2026, revealing a total revenue of $1.5 million, a significant increase from $244,000 in the same period last year. This growth was primarily driven by the recognition of $1.3 million in revenue from the Negotiation Agreement with Fuji Pharma, following the expiration of the agreement's exclusive negotiation period. Despite this increase in revenue, the company continues to face substantial operating losses, reporting a net loss of $13 million for the quarter, down from a loss of $15.1 million in the prior year.

The company's total operating expenses decreased to $14.8 million from $16 million year-over-year, attributed to reduced research and development costs, which fell to $10.9 million from $11.7 million. This decline reflects a decrease in clinical development expenses related to the PALISADE program for fasedienol, the company's lead product candidate for social anxiety disorder. General and administrative expenses also decreased to $3.9 million from $4.4 million, driven by reduced personnel costs following a workforce reduction in March 2026.

As of June 30, 2026, Vistagen's total assets amounted to $35.7 million, down from $48.6 million at the end of the previous fiscal quarter. The decrease in assets was primarily due to a reduction in cash and cash equivalents, which fell to $17 million from $30.8 million. The company reported an accumulated deficit of $490.3 million, highlighting the ongoing financial challenges it faces as it continues to invest in the development of its product candidates.

In terms of strategic developments, Vistagen is advancing its clinical pipeline, which includes five clinical-stage pherine product candidates. The company is focusing on fasedienol, which is currently in Phase 3 trials for social anxiety disorder, and has received fast track designation from the FDA. Additionally, Vistagen is exploring potential partnerships and collaborations to enhance its development efforts and secure additional funding. The company has indicated that it may seek further capital through equity or debt financing, as well as non-dilutive sources, to support its operations and product development initiatives.

Looking ahead, Vistagen anticipates continued operating losses as it progresses through its clinical trials and seeks regulatory approvals for its product candidates. The company has expressed uncertainty regarding its ability to fund operations beyond the next twelve months, emphasizing the need for additional capital to sustain its business. Furthermore, Vistagen is working to regain compliance with Nasdaq listing requirements, having received an extension until February 2027 to meet the minimum bid price requirement for its common stock.